Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
Inventors
Weinschenk, Toni • FRITSCHE, Jens • Singh, Harpreet • MAHR, Andrea • OTT, Martina • Wagner, Claudia • Schoor, Oliver
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12295996-B2
Publication Date
2025-05-13
Expiration Date
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Core Innovation
The disclosed subject matter describes an isolated peptide consisting of the amino acid sequence FLVDGSSAL (SEQ ID NO: 10) in the form of a pharmaceutically acceptable salt. The peptide is defined as an isolated peptide, and dependent disclosures specify particular salt forms and downstream pharmaceutical composition elements.
The document further describes peptide-containing pharmaceutical compositions in which the peptide FLVDGSSAL (SEQ ID NO: 10) is formulated with pharmaceutically acceptable carriers and, in some embodiments, with water and a buffer. Additional disclosures relate to adjuvants used in immune-therapy or vaccination contexts, including IL-12, IL-15, IL-21, and other adjuvant categories described in the disclosure.
In the broader disclosure, the document places the peptide into an immune therapy framework that includes antigen-presenting cell expression and vaccine use concepts, including multi-peptide constructs described as beads on a string and additional antigen-presenting cell context. The document also includes pancreatic cancer related peptide selection and evaluation concepts described as TUMAP/warehouse-based personalized peptide identification and evaluation by peptide presentation, immunogenicity, mass-spec assays, and peptide/MHC binding evaluation.
Claims Coverage
The partial content provides two independent claims directed to an isolated peptide of a defined amino-acid sequence in salt form. The dependent claims additionally define specific salt identity options and pharmaceutical composition or formulation components, and include a narrowed production option and an adjuvant example (IL-12).
Isolated peptide as a pharmaceutically acceptable salt
An isolated peptide consisting of the amino acid sequence FLVDGSSAL (SEQ ID NO: 10) in the form of a pharmaceutically acceptable salt.
Isolated peptide as a salt
An isolated peptide consisting of the amino acid sequence FLVDGSSAL (SEQ ID NO: 10) in the form of a salt.
Specific salt form (chloride salt)
The pharmaceutically acceptable salt is specified to be a chloride salt.
Pharmaceutical composition with a pharmaceutically acceptable carrier
A pharmaceutical composition is provided that includes the peptide together with a pharmaceutically acceptable carrier.
Pharmaceutical composition with water and a buffer
The pharmaceutical composition includes water and a buffer.
Production by solid phase synthesis or yeast/bacterial expression
A peptide in pharmaceutically acceptable salt form is produced either by solid phase peptide synthesis or by expression in a yeast cell or bacterial cell system.
Adjuvant featuring IL-12
In a pharmaceutical composition, the adjuvant is IL-12.
Across the provided claim set, the inventive coverage centers on the isolated peptide FLVDGSSAL (SEQ ID NO: 10) in salt form, with dependent claim refinements specifying particular salt identity, formulation components, a production or source option, and an adjuvant example.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?